Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Inclusion Criteria: 1. Male or female, aged between 18-65 years; 2. PLT\<20×10\^9/L or transfusion dependent on +D7 after haplo-HSCT; 3. Agree to receive the treatment of avatrombopag after Haplo-HSCT and sign the informed consent form. Exclusion Criteria: 1. With active infection; 2. ALT or AST\>3ULN, or total Bil\>2ULN 3. Ccr\<50 mL/min; 4. With the history of arteriovenous thrombosis; 5. With history of cardiovascular disease (such as NYHA Class III/IV congestive heart failure, arrhythmia that increases the risk of thromboembolic events \[such as atrial fibrillation\] and angina), and subjects who have undergone coronary stent implantation, angioplasty, or coronary artery bypass grafting; 6. With treatment of drugs to promote platelet production two weekes before enrollment, including but not limited to rhTPO and TPO-RA; 7. HBsAg or anti-HCV or anti-HIV positive; 8. Known to be allergic to avatrombopag and any of its excipients; 9. With secondary or multiple HSCT; 10. Females who were pregnant or breastfeeding or who had fertile ability but refuse to take effective contraceptive measures during and one month after this trial; 11. With any other clinical trial of investigational product or device within 30 days prior to the baseline visit, except for observational study; 12. Deemed unsuitable for enrollment by the investigator for any history of or concomitant medical condition. 13. Concomitant medication:The rhIL-11, rhTPO or TPO-RA(such as eltrombopag, hetrombopag and romiplostim) and desitabine, etc. were not allowed for use during this trial.